Lithium long-term treatment in mood disorders: Clinical and genetic predictors

Pharmacogenomics

Volumn 3, Issue 1, 2002, Pages 117-129

  Serretti, Alessandro ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

Dopamine receptors; Genetics; Manic depressive disorder; Pharmacogenetic; Serotonin receptors

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE 4 RECEPTOR; INOSITOL 1 PHOSPHATASE; LITHIUM; NONSTEROID ANTIINFLAMMATORY AGENT; RECEPTOR SUBUNIT; SEROTONIN TRANSPORTER; THIAZIDE DIURETIC AGENT; TRYPTOPHAN HYDROXYLASE;

AFFECTIVE NEUROSIS; ARTICLE; CONTROLLED STUDY; DISTRIBUTION VOLUME; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG MECHANISM; DRUG METABOLISM; DRUG RESPONSE; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; HERITABILITY; HUMAN; LONG TERM CARE; RECURRENT DISEASE;

CARRIER PROTEINS; HUMANS; LITHIUM; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; MOOD DISORDERS; NERVE TISSUE PROTEINS; PHARMACOGENETICS; POLYMORPHISM, GENETIC; SECOND MESSENGER SYSTEMS; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; TIME FACTORS; VARIATION (GENETICS);

EID: 0036209295     PISSN: 14622416     EISSN: None     Source Type: Journal    
DOI: 10.1517/14622416.3.1.117     Document Type: Article

References (209)

1. Prethymoleptic use of lithium
2. Lithium salts in the treatment of psychotic excitement
3. Practice guideline for the treatment of patients with bipolar disorder. American Psychiatric Association
4. Forty years of lithium treatment
5. Effects of lithium treatment and its discontinuation in bipolar manic-depressive disorders
6. Lithium in unipolar depression and the prevention of suicide
7. The impact of lithium prophylaxis on the course of bipolar disorder: A review of the research evidence
8. Does lithium treatment still work? Evidence of stable responses over three decades
9. Long-term treatment of bipolar disorder
10. Lithium treatment of bipolar affective disorders under naturalistic follow-up conditions
11. Lithium and recurrence in a long-term follow-up of bipolar affective disorder
12. Who responds to prophylactic lithium?
13. Who responds to prophylactic lithium therapy?
14. Unanswered questions, unknown future for one of our oldest medications
15. Current therapeutic profile of lithium
16. Lithium response and genetics of affective disorders
17. Predictors of lithium prophylaxis in bipolar patients
18. Factors associated with response to lithium prophylaxis in DSM III major depression and bipolar disorder
19. Melancholic features and response to lithium prophylaxis in mood disorders
20. Prediction of lithium response
21. Lithium prophylaxis in recurrent affective disorders
22. Psychosis as a predictor of response to lithium maintenance treatment in bipolar affective disorder
23. Predictors of long-term outcome of mood disorders on prophylactic lithium
24. Sex differences in response to lithium treatment
25. Prediction of response to stabilizing lithium treatment
26. Clinical and psychosocial predictors of recurrence in recovered bipolar and unipolar depressives: A one-year controlled prospective study
27. Previous pattern of course of the illness as a predictor of response to lithium prophylaxis in bipolar patients
28. Outcome of bipolar disorder on long-term treatment with lithium
29. Long-term outcome of lithium prophylaxis in bipolar disorder: A 5-year prospective study of 402 patients at a lithium clinic
30. Lithium maintenance treatment of depression and mania in bipolar I and bipolar II disorder
31. Long-term impact of lithium prophylaxis on the course of bipolar disorder
32. Early onset of lithium prophylaxis as a predictor of good long-term outcome
33. The challenge of predicting response to stabilising lithium treatment. The importance of patient selection
34. Genetic determinant of lithium ion distribution
35. Genetic determinant of lithium ion distribution: An in vitro and in vivo monozygotic-dizygotic twin study
36. Pharmacogenetics of lithium response in bipolar disorder
37. Intracellular lithium concentration and clinical response: Towards a mambrane theory of depression
38. Intracellular lithium and clinical response
39. Intracellular lithium concentration and clinical response
40. Intracellular lithium and clinical response
41. Interdependency of lithium ratio, plasma lithium level and clinical state in patients with affective disorders
42. Red blood cell plasma Li ratio variability in affective patients
43. Red blood cell lithium index and long-term maintenance treatment
44. Clinical and laboratory correlates of the response to long-term lithium treatment
45. Lithium ratio and maintenance treatment response
46. Only relatively higher and lower Li+ ratio might predict clinical responses
47. Red blood cell levels and lithium toxicity
48. Lithium in the elderly: A review with special focus on the use of intra-erytrocyte (RBC) levels in detecting serius impending neurotoxicity
49. Lithium ratio, phospholipids and the incidence of side effects
50. Lithium carbonate use in children and adolescents. A survey of the literature
51. Lithium in children of lithium-responding parents
52. Is response to prophylactic lithium a familial trait?
53. Psychiatric symptoms and syndromes among adolescent children of parents with lithium-responsive or lithium-nonresponsive bipolar disorder
54. Prediction of treatment outcome: Family and twin studies in lithium prophylaxis and the question of lithium red blood cell/plasma ratio
55. Outcomes on lithium treatment as a tool for genetic studies in affective disorders
56. Prediction of affective psychoses response to lithium prophylaxis. The role of socio-demographic, clinical, psychological and biological variables
57. Family history of affective disorders and the significance for prophylactic effect of lithium treatment
58. Lithium carbonate prophylaxis failure
59. 'Lithium non-responders' in a lithium clinic
60. A family study of bipolar I disorder in adolescence. Early onset of symptoms linked to increased familial loading and lithium resistance
61. Relationship between prophylactic effect of lithium therapy and family history of affective disorders
62. Family history and symptoms levels during treatment for bipolar I affective disorder
63. Mode of inheritance in families of patients with lithium-responsive affective disorders
64. The implications of genetics studies of major mood disorders for clinical practice
65. Treatment response to prophylactic lithium and family history of psychiatric disorders
66. Molecular mechanisms underlying mood stabilization in manic-depressive illness: The phenotype challenge
67. Pharmacogenomics of psychiatric disorders
68. Pharmacogenetics and the serotonin system: Initial studies and future directions
69. Antibipolar therapy: Mechanism of action of lithium
70. Signal transduction pathways
71. Lithium: Actions and mechanisms
72. Phospholipase C I and II brain isozymes: Immunohistochemical localization in neuronal systems in rat brain
73. Studies of inositol phospholipid-specific phospholipase C
74. Potentiation by lithium of CMP-phosphatidate formation in carbachol-stimulated rat cerebral-cortical slices and its reversal by myo-inositol
75. Biochemical, behavioral and clinical studies of the role of inositol in lithium treatment and depression
76. Neuronal and developmental actions of lithium: A unifying hypothesis
77. Temporal dissociation between lithium-induced changes in frontal lobe myo-inositol and clinical response in manic-depressive illness
78. Lithium regulation of brain myoinositol in bipolar affective disorder
79. A human myo-inositol monophosphatase gene (IMPA2) localized in a putative susceptibility region for bipolar disorder on chromosome 18p11.2: Genomic structure and polymorphism screening in manic-depressive patients
80. Lithium: A molecular transducer of mood-stabilization in the treatment of bipolar disorder
81. Lithium and brain signal transduction system
82. A molecular mechanism for the effect of lithium on development
83. Signalling pathways in the brain: Cellular transduction of mood stabilisation in the treatment of manic-depressive illness
84. Activation of the Wnt signaling pathway: A molecular mechanism for lithium action
85. Differential effect of lithium on fos protooncogene expression mediated by receptor and postreceptor activators of protein kinase C and cyclic adenosine monophosphate: Model for its antimanic action
86. Lithium augments fos protoonocogene expression in PC12 pheochromocytoma cells: Implications for therapeutic action of lithium
87. Lithium decrease membrane-associated protein kinase C in hippocampus: Selectivity for the alpha isozyme
88. Modulation of CNS signal transduction pathways and gene expression by mood stabilizing agents: Therapeutic implications
89. Concurrent measures of protein kinase C and phosphoinositides in lithium-treated bipolar patients and healthy individuals: A preliminary study
90. Lithium inhibits adrenergic and cholinergic increases in GTP binding in rat cortex
91. Regulation of adenylyl cyclase Type VI activity during desensitization of the A2a adenosine receptor-mediated cyclic AMP response, role for protein phosphatase 2A
92. Modulation of adenylyl cyclase in human keratinocytes by protein kinase C
93. Phorbol ester regulates stimulatory and inhibitory pathways of the hormone-sensitive adenylyl cyclase system in rat reticulocytes
94. Effects of lithium on second messenger systems in the brain
95. The mechanisms of action of lithium. II. Effects on adenylyl cyclase activity and beta-adrenergic receptor binding in normal subjects
96. Chronic lithium treatment robustly protects neurons in the central nervous system against excitotoxicity by inhibiting N-methyl-D-aspartate receptor-mediated calcium influx
97. Long-term lithium treatment suppresses p53 and Bax expression but increases Bcl-2 expression: A prominent role in neuroprotection against excitotoxicity
98. Lithium-induced increase in human brain grey matter
99. The Bcl-2 protein family: Arbiters of cell survival
100. The Bcl-2 gene family and apoptosis
101. Bcl-2 gene family in the nervous system
102. Apoptosis: Unmasking the executioner
103. Clinical and preclinical evidence for the neurotrophic effects of mood stabilizers: Implications for the pathophysiology and treatment of manic-depressive illness
104. Lithium upregulates the cytoprotective protein Bcl-2 in the CNS in vivo: A role for neurotrophic and neuroprotective effects in manic depressive illness
105. Lithium at 50: Have the neuroprotective effects of this unique cation been overlooked
106. Subgenual prefrontal cortex abnormalities in mood disorders
107. Lithium attenuates p53 levels in human neuroblastoma SH-SY5Y cells
108. Differential effects of mood stabilizers on Fos/Jun proteins and AP-1 DNA binding activity in human neuroblastoma SH-SY5Y cells
109. Lithium increases transcription factor binding to AP-1 and cyclic AMP-responsive element in cultured neurons and rat brain
110. Regulation of signal transduction pathways by mood-stabiling agents. Implication for the pathophysiology and treatment of bipolar disorder
111. Intricate regulation of tyrosine hydroxylase activity and gene expression
112. Lithium chloride induces the expression of tyrosine hydroxylase in hNT neurons
113. Potentiation of astroglial nitric oxide synthase type-2 expression by lithium chloride
114. Intracellular calcium ions in affective disorders: A review and an hypothesis
115. Calcium antagonists in mania: A double-blind study of verapamil
116. Mode of action of lithium in affective disorders. An influence on intracellular calcium functions
117. Calcium channel blockers
118. Lithium stimulates glutamate 'release' and inositol 1,4,5-triphosphate accumulation via activation of the N-methyl-D-aspartate receptor in monkey and mouse cerebral cortex slices
119. Lithium acutely inhibits and chronically upregulates and stabilizes glutamate uptake by presynaptic nerve endings in mouse cerebral cortex
120. 2+ in mammalian neurons
121. Time-dependent effects of lithium on the agonist-stimulated accumulation of second messenger inositol 1,4,5-triphosphate in SH-SY5Y human neuroblastoma cells
122. Lithium increases tyrosine hydroxylase levels both in vivo and in vitro
123. GABA and mood disorders: A brief review and hypothesis
124. Chronic pharmacological treatment with certain antidepressants alters the expression and DNA-binding activity of transcription factor AP-2
125. Lithium ions enhance cysteine string protein gene expression in vivo and in vitro
126. The effect of lithium on methamphetamine-induced regional Fos protein expression in the rat brain
127. Muscarinic receptor regulation and protein kinase C: Sites for the action of chronic lithium in the hippocampus
128. Chronic lithium administration alters a prominent PKC substrate in rat hippocampus
129. A bimodal model of the mechanism of action of lithium
130. Relationship between depression and mania
131. The serotonin hypothesis of depression
132. Lithium and serotonin function: Implications for the serotonin hypothesis of depression
133. Machanisms of action of lithium in affective illness: Basic and clinical implications
134. A review of biochemical and neuropharmacological actions of lithium
135. 5-HT neuroendocrine response during psychotropic drug tretmant: An investigation of the effects of lithium
136. Cerebrospinal fluid levels of MHPG in affective disorders
137. Biogenic amine metabolites in the cerebrospinal fluid of depressed and maniac patients
138. Cerebrospinal fluid 5-hydroxyindoleacetic acid and homovanillic acid in psychiatric patients
139. 5-Hydroxyindolacetic acid and homovanillic acid in cerebrospinal fluid in manic-depressive psychosis
140. The effect of lithium treatment on manic symptoms and levels of monoamine metabolites in cerebrospinal fluid of manic depressive patients
141. Clinical effects and cerebrospinal fluid acid monoamine metabolites
142. Cerebrospinal fluid and plasma monoamines and their metabolites in euthymic bipolar patients
143. Lithium carbonate treatment of mania: Cerebrospinal fluid and urinary monoamine metabolites and treatment outcome
144. The effects of antidepressant treatments and lithium upon 5-HT1A receptor function
145. Effects of chronic lithium treatment on serotonin binding sites in rat brain
146. 1B receptors: A novel target for lithium. Possible involvement in mood disorders
147. Regulation of central serotonin transporters by chronic lithium: An autoradiographic study
148. 1A receptors
149. Serotonin in mania and in the mechanism of action of mood stabilizers: A review of clinical studies
150. Effects of lithium carbonate on serotonin uptake in blood platelets of patients with affective disorders
151. Short-term lithium administration to healthy volunteers produces long-lasting pronounced changes in platelet serotonin uptake but not imipramine binding
152. Stimulation by lithium on monoamine uptake in human platelets
153. Studies on human blood platelets in affective disorders/
154. Long-term effect of lithium on the uptake of 5-hydroxytryptamine by human platelets
155. Lithium restores abnormal platelet 5-HT transport in patients with affective disorders
156. Neurochemical changes during discontinuation of lithium prophylaxis. II. Alterations in platelet serotonin function
157. Increased plasma free serotonin but unchanged platelet serotonin in bipolar patients treated chronically with lithium
158. Lithium treatment and serotoninergic function. Neuroendocrine and behavioral responses to iv. tryptophan in affective disorder
159. Long-term lithium treatment causes serotonin receptor downregulation via serotonergic presynapses in rat brain
160. Tryptophan depletion in recently manic patients treated with lithium
161. Serotonin does not mediate the adrenal catecholamine-releasing effect of acute lithium administration in rats
162. Lithium reduced synaptic transmission and increased neuronal excitability without altering endogenous serotonin, noradrenaline and dopamine in rat hippocampal slices in vitro
163. The mechanisms of action of lithium. I. Effects on serotoninergic and noradrenergic systems in normal subjects
164. Lithium attenuates the activation-euphoria but not the psychosis induced by D-amphetamine in schizophrenia
165. Lithium and bupropion antagonise the phasic changes in locomotor activity caused by dopamine infused into the rat nucleus accumbens
166. Acute effects of lithium on dopaminergic responses: Iontophoretic studies in the rat visual cortex
167. Adaptive changes in the rat dopaminergic transmission following repeated lithium administration
168. Effects of a chronic lithium treatment on central dopamine neurotransporters
169. Chronic lithium attenuates dopamine D1-receptor mediated increases in acetylcholine release in rat frontal cortex
170. Acute effects of lithium on catecholamines, serotonin and their major metabolites in discrete brain regions
171. The neurobiology of treatment-resistant mood disorders
172. Cholinergic transduction
173. Ongoing lithium treatment prevents relapse after total sleep deprivation
174. Serotonin-dopamine interaction and its relevance to schizophrenia
175. 2 receptors
176. Serotonin inhibits acetylcholine release from rat striatum slices: Evidence for a presynaptic receptor-mediated effect
177. Modulation of central cholinergic activity by GABA and serotonin: PET studies with 11C-bentropine in primates
178. Effects of central cholinergic blockade on striatal dopamine release measured with positron emission tomography in normal human subjects
179. A long-term retrospective follow-up study of patients treated with prophylactic lithium carbonate
180. Outcome of lithium prophylaxis - A prospective follow-up of affective disorder patients assigned to high and low serum lithium levels
181. Use of unlinked genetic markers to detect population stratification in association studies
182. A study of relapses in subjects with mood disorder on lithium treatment. Eur
183. A 24-month follow-up study of unipolar subjects: A comparison between lithium and fluvoxamine
184. Tryptophan hydroxylase gene and response to lithium prophylaxis in mood disorders
185. Dopamine receptor D2, D4, GABAA alpha-1 subunit genes and response to lithium prophylaxis in mood disorders
186. Dopamine receptor D3 gene and response to lithium prophylaxis in mood disorders
187. Serotonin receptor 2A, 2C, 1A genes and response to lithium prophylaxis in mood disorders
188. Serotonin transporter gene associated with lithium prophylaxis in mood disorders
189. Lithium response: Association study with two candidate genes
190. Research diagnostic criteria: Rationale and reliability
191. No association between chromosome-18 markers and lithium-responsive affective disorders
192. Lithium responsive bipolar disorder, unilineality and chromosome 18: A linkage study
193. Lithium-responsive affective disorders: No association with the tyrosine hydroxylase gene
194. Association and linkage studies of candidate genes involved in GABAergic neurotransmission in lithium-responsive bipolar disorder
195. Association and linkage studies of CRH and PENK genes in bipolar disorder: A collaborative IGSLI study
196. MAOA: Association and linkage studies with lithium responsive bipolar disorder
197. Polyglutamine tracts: No evidence of a major role in bipolar disorder
198. Polyglutamine coding genes in bipolar disorder: Lack of association with selected candidate loci
199. Evidence for a role of phospholipase C-gamma1 in the pathogenesis of bipolar disorder
200. Lack of genetic variation in the coding region of the myo-inositol monophosphatase gene in lithium-treated patients with manic depressive illness
201. The polymorphic inositol polyphosphate 1-phosphatase gene as a candidate for pharmacogenetic prediction of lithium-responsive manic-depressive illness
202. Pharmacogenomics to predict drug response
203. Genotypic association between the dopamine D3 receptor and tardive dyskinesia in chronic schizophrenia
204. Genetic determinants of clozapine-induced agranulocytosis: Recent results of HLA subtyping in a non-jewish caucasian sample
205. Microchip arrays put DNA on the spot
206. Experimental annotation of the human genome using microarray technology